Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, James; Chiarion‐Sileni, Vanna; González, René; Grob, Jean‐Jacques; Lance Cowey, C.; D. Lao, Christopher; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Francesco Ferrucci, Pier; Hill, Andrew; Wagstaff, John; S. Carlino, Matteo; B.A.G. Haanen, John; Maio, Michele; Márquez‐Rodas, Iván; A. McArthur, Grant; A. Ascierto, Paolo; V. Long, Georgina; K. Callahan, Margaret; A. Postow, Michael; F. Grossmann, Kenneth; Sznol, Mario; Dréno, Brigitte; Bastholt, Lars; Yang, Arvin; M. Rollin, Linda; E. Horak, Christine; Stephen Hodi, F.; D. Wolchok, Jedd

doi:10.1056/nejmoa1504030

Public

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Published in New England Journal of Medicine • May 31, 2015

Authors:

James Larkin

Vanna Chiarion‐Sileni

René González

Abstract

BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alon...

Subject

Nivolumab

Ipilimumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!